Ticker

Oxford Nanopore Technologies PLC (LSE:ONT) secured an upgrade to a 'buy' rating from Panmure Liberum on Monday, as analysts cheered a lucrative diagnostics deal despite lingering strategic risks. The shares traded at 165.90p, down 2.41%, even as the broker hiked its target price to 196 pence from 170 pence to reflect the evolving business model.

Oxford Nanopore Technologies plc (OXFYY) Q2 2026 Earnings Call Transcript

Oxford Nanopore Technologies LON: ONT reported first-half revenue growth below its expectations as declines in China, the Middle East and delayed orders in the Americas weighed on performance, while gross-margin expansion and lower operating expenses narrowed its adjusted EBITDA loss.

Oxford Nanopore Technologies PLC (LSE:ONT), the DNA-sequencing technology company, has set a target of more than $700 million in annual revenue by 2030 as it maps out a path to profitability. The company also expects its margin on adjusted earnings, a measure of underlying profitability that excludes items such as interest, tax and depreciation, to exceed 15% by the same date.

Shares in Oxford Nanopore Technologies PLC (LSE:ONT) fell 16% to 101.2 pence after the company said first-half trading had come in below management expectations. The maker of nanopore-based technology for analysing DNA and RNA, expects revenue of around £116.5 million for the six months to 30 June.